Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...
Hosted on MSN6mon
Bristol Myers gets $6.4B Celgene CVR case dismissed: reportUnder the deal, Celgene shareholders received $50 in cash plus a tradeable CVR for each share held, with the CVR entitling the holder to $9 in cash if certain regulatory milestones were achieved ...
Under the deal, Celgene shareholders received $50 in cash plus a tradeable CVR for each share held, with the CVR entitling ...
Celgene's extensive trial programme showed the drug provided benefits comparable to those seen in patients taking TNF blocker drugs. Celgene’s psoriatic arthritis drug Otezla approved | pharmaphorum ...
Celgene has acquired Gloucester Pharmaceuticals for US$340 million upfront and up to $300 million in milestones. Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone ...
Companies like Celgene, Biogen Idec, and Gilead Sciences all took top spots on our list of the Best Employers in America. Clearly there are a lot of people who love working in pharma and biotech ...
Celgene (Warren, NJ), a developer of chirally pure drugs, agreed on June 30 to purchase gene-regulation firm Signal Pharmaceuticals (San Diego, CA) for $200 million in an all-stock deal.
Torres has teamed up with SHOW MORE OF YOU from Celgene and Otezla — a campaign that is shining light on the psoriasis or psoriatic arthritis. To learn more about psoriatic disease, visit the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results